Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT05552651Phase 2Unknown
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Pathological Complete Response at 6 months. Status: unknown.
02
Drugs
envafolimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05552651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552651.